Outlook Therapeutics, Inc. has appointed Kevin Lundquist Chief Financial Officer, effective September 1, 2026, succeeding Lawrence “Larry” Kenyon as the company prepares for the U.S. commercial launch of LYTENAVA. CEO Bob Jahr thanked Kenyon “for his many years of leadership and service,” saying his “unwavering dedication and valuable contributions helped guide the Company through years of clinical and regulatory advancements culminating in the FDA approval of LYTENAVA.”
About Kevin Lundquist
Jahr said “FDA approval of LYTENAVA fundamentally changes the opportunity in front of Outlook Therapeutics, and Kevin is exactly the caliber of executive we need as we enter this next phase,” citing his “exceptional combination of financial and operational leadership, capital markets expertise, and experience leading finance functions across large-scale pharmaceutical and commercial organizations.” Lundquist called it “an extraordinary time to join Outlook Therapeutics,” noting that LYTENAVA’s FDA approval “provides the foundation from which to build its U.S. market presence.” He said his priorities will include “maintaining financial discipline, allocating capital toward the Company’s highest-value opportunities, and ensuring Outlook has the resources and capabilities needed to execute its U.S. launch strategy.”
Lundquist joins Outlook from CapsoVision, Inc., a medical technology company, where he served as Chief Financial Officer and led the company through its initial public offering in July 2025. Before that, he was CFO of Abzena Biologics, a private equity-backed contract development and manufacturing organization, where he oversaw financial and strategic direction, IPO preparation, and long-term strategy. He also served as Vice President of Finance at Revance Therapeutics, overseeing financial operations, SEC reporting, treasury, capital raises, and M&A.
Earlier in his career, Lundquist was Global Head of Finance for Genentech/Roche’s Drug Substance Biologics Operations, supporting the company’s global biologics manufacturing network, and served as Chief Financial Officer of Caterpillar’s Japan division, overseeing a business with $6 billion in annual revenue. He began his career in various finance and corporate audit roles at Abbott Laboratories.
Lundquist holds a Master of Business Administration in Finance from Utah State University and a Bachelor of Science in Accounting and Finance from the University of Utah.
About Outlook Therapeutics
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg in the U.S., bevacizumab gamma in the E.U.), the only ophthalmic formulation of bevacizumab to receive U.S. FDA approval and European Commission and MHRA Marketing Authorization for the treatment of wet age-related macular degeneration. Outlook Therapeutics has commenced commercial launch of LYTENAVA in Germany, Austria, and the UK, and is preparing for its U.S. commercial launch following FDA approval in July 2026.
